This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

Inclusion Criteria:

• Have a diagnosis of HS for at least 12 months.
• Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
• Have an (abscess plus inflammatory nodule) count of at least 5.
• Agree to use topical antiseptics daily.
• Had an inadequate response or intolerance to a 28-day course of oral antibiotics.

Exclusion Criteria:

• Have more than 20 draining fistulae.
• Have had surgical treatment for HS in the last 4 weeks before randomization.
• Have an active skin disease or condition, that could interfere with the assessment of HS.
• Have a current or recent acute, active infection.
• Are immunocompromised.
• Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.